Skip to main content

Table 2 Univariate and multivariate analyses of outcomes between lower and higher eGDR group in AIS patients

From: Insulin resistance estimated by estimated glucose disposal rate predicts outcomes in acute ischemic stroke patients

 

N(%)

Model 1*

Model 2†

Model 3‡

OR(95%CI)

P-value

OR(95%CI)

P-value

OR(95%CI)

P-value

follow-up in 3 months

       

stroke recurrence

       

lower eGDR group

117 (6.74)

Ref.

 

Ref.

 

Ref.

 

higher eGDR group

223 (4.92)

0.72(0.58,0.91)

< 0.01

0.71(0.57,0.89)

< 0.01

0.81(0.61,1.06)

0.12

favorable functional outcome (mRs 0–2)

       

lower eGDR group

1524 (87.79)

Ref.

 

Ref.

 

Ref.

 

higher eGDR group

4031 (88.89)

1.11(0.94,1.32)

0.22

1.17(0.98,1.39)

0.08

1.16(0.94,1.43)

0.16

excellent functional outcome (mRs 0–1)

       

lower eGDR group

1275 (73.44)

Ref.

 

Ref.

 

Ref.

 

higher eGDR group

3539 (78.04)

1.28(1.13,1.46)

< 0.01

1.33(1.17,1.51)

< 0.01

1.24(1.06,1.45)

< 0.01

follow-up in one year

       

stroke recurrence

       

lower eGDR group

165 (9.5)

Ref.

 

Ref.

 

Ref.

 

higher eGDR group

354 (7.81)

0.81(0.68,0.98)

0.03

0.80(0.67,0.96)

0.02

0.91(0.73,1.14)

0.41

combined vascular event

       

lower eGDR group

167 (9.62)

Ref.

 

Ref.

 

Ref.

 

higher eGDR group

366 (8.07)

0.83(0.69,1.00)

0.05

0.82(0.68,0.98)

0.03

0.93(0.75,1.17)

0.54

favorable functional outcome (mRs 0–2)

       

lower eGDR group

1543 (88.88)

Ref.

 

Ref.

 

Ref.

 

higher eGDR group

4109 (90.61)

1.21(1.01,1.44)

0.04

1.30(1.08,1.56)

< 0.01

1.55(1.24,1.93)

< 0.01

excellent functional outcome (mRs 0–1)

       

lower eGDR group

1344 (77.42)

Ref.

 

Ref.

 

Ref.

 

higher eGDR group

3667 (80.86)

1.23(1.08,1.41)

< 0.01

1.29(1.13,1.48)

< 0.01

1.28(1.09,1.51)

< 0.01

  1. OR, odds ratio; eGDR, estimated glucose disposal rate; *Model 1 was unadjusted; †Model 2 was adjusted for age and sex; ‡Model 3 was adjusted for age, sex, type 1 diabetes (T1D), type 2 diabetes (T2D), lipid metabolism disorder, coronary heart disease, atrial fibrillation, infection within 2 weeks before admission, sleep apnea, drinking, body mass index (BMI), high density lipoprotein, triglycerides, thrombolysis, hypoglycemic therapy, antiplatelet therapy and anticoagulant therapy.